Publication Year: 2012
-
Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial
-
Serum Proteomic Classification in Refractory Non-Small-Cell Lung Cancer Treated with Erlotinib +/- Pazopanib in a Randomized Placebo-Controlled Phase II Study
-
A phase 2 adjuvant trial of gi-4000 plus gem vs. Gem alone in ras mutation+ resected pancreas cancer: r1 subgroup and proteomic analysis
-
VeriStrat has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
-
A plasma proteomic signature predicts outcomes in a Phase 3 study of gemcitabine (G) + cisplatin (C) ± sorafenib in first line stage IIIB or IV non-small cell lung cancer (NSCLC)
-
EarlyCDT—Lung Test: Improved Clinical Utility Through Additional Autoantibody Assays
-
Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors